[go: up one dir, main page]

CO2017005624A2 - Composiciones oftálmicas estabilizadas de omega 3 - Google Patents

Composiciones oftálmicas estabilizadas de omega 3

Info

Publication number
CO2017005624A2
CO2017005624A2 CONC2017/0005624A CO2017005624A CO2017005624A2 CO 2017005624 A2 CO2017005624 A2 CO 2017005624A2 CO 2017005624 A CO2017005624 A CO 2017005624A CO 2017005624 A2 CO2017005624 A2 CO 2017005624A2
Authority
CO
Colombia
Prior art keywords
ophthalmic compositions
stabilized
stabilized omega
omega
keratoconjunctivitis
Prior art date
Application number
CONC2017/0005624A
Other languages
English (en)
Inventor
Anuradha V Gore
Jaya Giyanani
Sukhon Likitlersuang
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54784036&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO2017005624(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of CO2017005624A2 publication Critical patent/CO2017005624A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/55—Linaceae (Flax family), e.g. Linum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se proporcionan composiciones oftálmicas estabilizadas que contienen aceites omega 3, que son útiles como lágrimas artificiales y como composiciones oftálmicas para diagnosticar, tratar o prevenir la queratoconjuntivitis o síndrome del ojo seco en un ser humano u otro mamífero.
CONC2017/0005624A 2014-11-25 2017-06-06 Composiciones oftálmicas estabilizadas de omega 3 CO2017005624A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462083980P 2014-11-25 2014-11-25
PCT/US2015/062213 WO2016085885A1 (en) 2014-11-25 2015-11-23 Stabilized omega-3 ophthalmic compositions

Publications (1)

Publication Number Publication Date
CO2017005624A2 true CO2017005624A2 (es) 2017-10-20

Family

ID=54784036

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2017/0005624A CO2017005624A2 (es) 2014-11-25 2017-06-06 Composiciones oftálmicas estabilizadas de omega 3

Country Status (17)

Country Link
US (5) US10279005B2 (es)
EP (1) EP3223794A1 (es)
JP (1) JP6768653B2 (es)
KR (1) KR102487299B1 (es)
CN (1) CN107106483B (es)
AU (1) AU2015353701B2 (es)
CA (1) CA2967413C (es)
CL (1) CL2017001301A1 (es)
CO (1) CO2017005624A2 (es)
IL (1) IL252161B (es)
MX (2) MX372988B (es)
NZ (1) NZ732058A (es)
PH (1) PH12017500922A1 (es)
RU (1) RU2697844C9 (es)
SG (1) SG11201704167PA (es)
UA (1) UA121399C2 (es)
WO (1) WO2016085885A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019524892A (ja) 2016-08-19 2019-09-05 アクリビスタ エルエルシーＡｋｒｉｖｉｓｔａ，Ｌｌｃ ドライアイ症候群を診断及び治療する方法ならびにヒト眼を治療するための組成物
WO2019036625A1 (en) 2017-08-18 2019-02-21 Akrivista, LLC METHODS FOR DIAGNOSING AND TREATING DRY-LIKE SYNDROME AND COMPOSITIONS FOR TREATING A HUMAN EYE
IL272601B2 (en) * 2017-08-27 2025-03-01 Rhodes Tech Inc Pharmaceutical compositions for the treatment of ophthalmic conditions
CN109364153A (zh) * 2018-11-30 2019-02-22 河南科高中标检测技术有限公司 一种缓解和治疗电子辐射类视疲劳的组合物、制备方法及其应用
CN114096339B (zh) 2019-05-02 2024-04-12 特清公司 从滴眼剂中去除防腐剂
AU2020405238A1 (en) * 2019-12-19 2022-07-14 TearClear Corp. Preservative removal from eye drops
KR102365008B1 (ko) * 2020-06-23 2022-02-23 주식회사태준제약 디쿠아포솔을 포함하는 점안 조성물
CN115996705A (zh) * 2020-06-23 2023-04-21 株式会社泰俊制药 包含地夸磷索的眼用组合物
MX2023001557A (es) 2020-08-05 2023-03-08 Tearclear Corp Sistemas y metodos para la eliminacion de conservantes de formulaciones oftalmaticas.
US11951123B2 (en) 2022-01-12 2024-04-09 Platform Ophthalmic Innovations, LLC Fortified nutritional lubricating drops for dry eye disease
US12397017B2 (en) 2022-01-12 2025-08-26 Platform Ophthalmic Innovations, LLC Fortified nutritional lubricating drops for dry eye disease
IT202300000006A1 (it) 2023-01-02 2024-07-02 Offhealth Spa “formulazione liposomiale di curcumina per uso oftalmico e suo metodo di preparazione industriale atto a stabilizzare nel tempo la concentrazione della stessa curcumina”
WO2025072929A1 (en) * 2023-09-28 2025-04-03 The Regents Of The University Of California Methods and compositions of treating age-related conditions

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4201706A (en) 1978-09-22 1980-05-06 Burton, Parsons & Company, Inc. Treatment of corneal edema
EP0028110B1 (en) 1979-10-26 1984-03-07 Smith and Nephew Associated Companies p.l.c. Autoclavable emulsions
JPS56104814A (en) 1980-01-25 1981-08-20 Kunihiro Okanoe Preparation of eye drop
US4649047A (en) 1985-03-19 1987-03-10 University Of Georgia Research Foundation, Inc. Ophthalmic treatment by topical administration of cyclosporin
ATE109970T1 (de) 1987-09-03 1994-09-15 Univ Georgia Res Found Cyclosporin-augenmittel.
US4839342A (en) 1987-09-03 1989-06-13 University Of Georgia Research Foundation, Inc. Method of increasing tear production by topical administration of cyclosporin
FR2638089A1 (fr) 1988-10-26 1990-04-27 Sandoz Sa Nouvelles compositions ophtalmiques a base d'une cyclosporine
IT1224795B (it) 1988-12-01 1990-10-24 Sigma Tau Ind Farmaceuti Uso dell'acetil d-carnitina nel trattamento terapeutico del glaucoma e composizioni farmaceutiche utili in tale trattamento
CA2037057C (en) 1989-08-03 1995-03-21 Takakazu Morita Photostabilizing method for ophthalmic solutions and the resulting opthalmic solutions therefrom
US5681555A (en) 1991-04-22 1997-10-28 Gleich; Gerald J. Method for the treatment of bronchial asthma by parenteral administration of anionic polymers
DE4229494A1 (de) 1992-09-04 1994-03-10 Basotherm Gmbh Arzneimittel zur topischen Anwendung am Auge zur Behandlung des erhöhten intraokularen Drucks
US5474979A (en) 1994-05-17 1995-12-12 Allergan, Inc. Nonirritating emulsions for sensitive tissue
CA2199610A1 (en) 1994-09-14 1996-03-21 Taisho Pharmaceutical Co., Ltd. Eye drops for repairing repairing corneal damage
US5980865A (en) 1995-08-18 1999-11-09 Baker Norton Pharmaceuticals, Inc. Method for treating late phase allergic reactions and inflammatory diseases
FI106923B (fi) 1997-01-03 2001-05-15 Cultor Ltd Finnsugar Bioproduc Trimetyyliglysiinin käyttö kehon limakalvojen hygieniaan ja hoitoon tarkoitetuissa valmisteissa
AR002194A1 (es) 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.
US5981607A (en) 1998-01-20 1999-11-09 Allergan Emulsion eye drop for alleviation of dry eye related symptoms in dry eye patients and/or contact lens wearers
IT1302307B1 (it) 1998-09-01 2000-09-05 Sigma Tau Healthscience Spa Composizione ad attivita' antiossidante ed atta a migliorarel'utilizzazione metabolica del glucosio, comprendente acetil
AU1295200A (en) 1998-11-13 2000-06-05 Continental Projects Limited Complexes of hyaluronic acid/carnitines and pharmaceutical and cosmetic compositions
US6228392B1 (en) 1999-04-29 2001-05-08 Gene Tools, Llc Osmotic delivery composition, solution, and method
EP1301210A2 (en) 2000-07-14 2003-04-16 Allergan, Inc. Compositions containing therapeutically active components having enhanced solubility
AU781975B2 (en) 2000-09-14 2005-06-23 Hayashibara Co., Ltd Pharmaceutical composition for ophthalmic use
ATE443749T1 (de) 2000-11-08 2009-10-15 Fxs Ventures Llc Verbesserte ophthalmische und kontaktlinsenlösungen mit einfachen sacchariden als konservierungsverbesserer
US7045121B2 (en) 2001-12-14 2006-05-16 Allergan, Inc. Ophthalmic compositions for lubricating eyes and methods for making and using same
WO2004028536A1 (en) 2002-09-30 2004-04-08 Babizhayev Mark A Method for topical treatment of eye disease and composition and device for said treatment
US20040137079A1 (en) 2003-01-08 2004-07-15 Cook James N. Contact lens and eye drop rewetter compositions and methods
US6635654B1 (en) 2003-01-09 2003-10-21 Allergan, Inc. Ophthalmic compositions containing loratadine
US20060251685A1 (en) 2003-03-18 2006-11-09 Zhi-Jian Yu Stable ophthalmic oil-in-water emulsions with Omega-3 fatty acids for alleviating dry eye
JPWO2004084877A1 (ja) 2003-03-26 2006-06-29 株式会社メニコン 眼科用組成物
ZA200510025B (en) * 2003-06-11 2007-03-28 Novacea Inc Pharmaceutical compositions comprising active vitamin D compounds
US20050009836A1 (en) 2003-06-26 2005-01-13 Laskar Paul A. Ophthalmic composition containing quinolones and method of use
US20070265341A1 (en) 2004-07-01 2007-11-15 The Schepens Eye Research Institute Inc. Compositions and methods for treating eye disorders and conditions
KR20070040381A (ko) 2004-07-01 2007-04-16 셰펜스 아이 리써치 눈의 장애 및 상태를 치료하는 조성물 및 방법
US8569367B2 (en) 2004-11-16 2013-10-29 Allergan, Inc. Ophthalmic compositions and methods for treating eyes
US7297679B2 (en) 2005-07-13 2007-11-20 Allergan, Inc. Cyclosporin compositions
US9561178B2 (en) 2006-07-25 2017-02-07 Allergan, Inc. Cyclosporin compositions
WO2008035246A2 (en) 2006-07-28 2008-03-27 Novagali Pharma Sa Compositions containing quaternary ammonium compounds
WO2008027341A2 (en) 2006-08-30 2008-03-06 Merck & Co., Inc. Topical ophthalmic formulations
CN101668511A (zh) 2007-02-28 2010-03-10 阿西克斯医疗公司 正常化睑板腺分泌的方法和化合物
JP4929245B2 (ja) 2008-07-31 2012-05-09 株式会社ベッセル工業 工具類のグリップ
WO2010047927A1 (en) 2008-10-20 2010-04-29 Allergan, Inc. Ophthalmic compositions useful for improving visual acuity
IT1393419B1 (it) * 2009-03-19 2012-04-20 Medivis S R L Composizioni oftalmiche a base di acidi grassi polinsaturi omega-3 e omega-6.
US9480645B2 (en) * 2009-06-02 2016-11-01 Abbott Medical Optics Inc. Omega-3 oil containing ophthalmic emulsions
EP2437762B1 (en) * 2009-06-05 2017-08-09 Allergan, Inc. Artificial tears and therapeutic uses
US8957048B2 (en) 2011-10-06 2015-02-17 Allergan, Inc. Compositions for the treatment of dry eye
RU2014129268A (ru) * 2011-12-16 2016-02-10 Аллерган, Инк. Офтальмологические составы, которые содержат привитые сополимеры поливинилкапролактам-поливинилацетат-полиэтиленгликоля
CN102934703B (zh) * 2012-11-13 2015-07-15 中国食品发酵工业研究院 一种亚麻籽油微胶囊及其生产方法

Also Published As

Publication number Publication date
US20190298790A1 (en) 2019-10-03
EP3223794A1 (en) 2017-10-04
US20250228913A1 (en) 2025-07-17
KR102487299B1 (ko) 2023-01-10
KR20170086111A (ko) 2017-07-25
NZ732058A (en) 2023-06-30
RU2017117558A3 (es) 2019-06-05
JP2017535578A (ja) 2017-11-30
PH12017500922A1 (en) 2017-11-20
MX372988B (es) 2020-04-06
CN107106483B (zh) 2021-04-16
US20240299480A1 (en) 2024-09-12
CN107106483A (zh) 2017-08-29
MX2020004076A (es) 2020-07-29
UA121399C2 (uk) 2020-05-25
IL252161A0 (en) 2017-07-31
CA2967413A1 (en) 2016-06-02
JP6768653B2 (ja) 2020-10-14
WO2016085885A1 (en) 2016-06-02
BR112017010987A2 (pt) 2018-02-14
RU2017117558A (ru) 2018-12-26
RU2697844C9 (ru) 2019-10-01
US20160143977A1 (en) 2016-05-26
RU2697844C2 (ru) 2019-08-21
CA2967413C (en) 2023-08-15
AU2015353701A1 (en) 2017-06-01
AU2015353701B2 (en) 2021-03-25
CL2017001301A1 (es) 2018-01-26
IL252161B (en) 2020-09-30
MX2017006474A (es) 2017-09-12
US20220143122A1 (en) 2022-05-12
US10279005B2 (en) 2019-05-07
SG11201704167PA (en) 2017-06-29

Similar Documents

Publication Publication Date Title
CO2017005624A2 (es) Composiciones oftálmicas estabilizadas de omega 3
BR112019006160A2 (pt) composições e métodos para o tratamento das condições oftálmicas
MX389460B (es) Composiciones y metodos de uso en nintedanib para tratar enfermedades oculares con neovascularizacion anormal.
MX2020001340A (es) Modelos celulares y terapias para enfermedades oculares.
ECSP19044183A (es) (aza)indol-, benzotiofen, y benzofuran-3-sulfonamidas
CL2018001478A1 (es) Agonistas del receptor de apelina y métodos de uso
MX2017014375A (es) Moduladores del ccr2.
CO2017004715A2 (es) Métodos y formulaciones para tratar enfermedades vasculares de los ojos
MX2018003388A (es) Agonistas del receptor farnesoide x y usos de los mismos.
MX2017016517A (es) Composiciones estables al almacenamiento y metodos para el tratamiento de errores de refraccion del ojo.
WO2016040775A3 (en) Apparatus and methods for identifying and evaluating bright spot indications observed through optical coherence tomography
MX388380B (es) Composiciones para usarse en el incremento de los niveles de glóbulos rojos y el tratamiento de enfermedad de células falciformes.
AR091237A1 (es) Composiciones que comprenden un aptamero anti factor de crecimiento derivado de plaquetas (anti-pdgf) y un antagonista de factor de crecimiento de endotelio vascular (vegf)
CR20190239A (es) Inhibidores de la magl
AR096478A1 (es) Composiciones para el tratamiento de superficie que comprenden tintes fotocromáticos
EA201992170A1 (ru) Модуляторы экспрессии pcsk9
DOP2018000219A (es) Anticuerpos anti-factor bb del complemento y usos de estos
CO2018005393A2 (es) Anticuerpos anti-htra1 y métodos de uso de los mismos
AR100231A1 (es) Composiciones para el cuidado de las telas que comprenden polímeros de poliuretano, poliurea y/o poliuretanourea
MY193650A (en) Extracellular matrix compositions
CO2018007237A2 (es) Reguladores del cftr y métodos para su uso
MX392383B (es) Metodos para tratar afecciones oculares.
BR112017011685A2 (pt) composições compreendendo 15-hepe e métodos de tratamento ou prevenção da fibrose usando as mesmas
MX377022B (es) Composiciones de lágrimas artificiales.
EA201790391A1 (ru) Композиции для ингибирования воспаления у субъекта с повреждением спинного мозга и способы их применения